<DOC>
	<DOCNO>NCT02920918</DOCNO>
	<brief_summary>Investigator Initiated Study study effect Canagliflozin 100 milligram ( mg ) v Sitagliptin 100 mg parameter aerobic exercise capacity ( peak oxygen consumption [ VO2 ] ) ventilator efficiency ( minute ventilation [ VE ] /carbon dioxide production [ VCO2 ] slope ) cardiopulmonary exercise test ( CPET ) 12 week active treatment ( primary endpoint ) . Blood pressure ( BP ) , body water content , body composition , cardiac function , diet also measure ( secondary endpoint ) .</brief_summary>
	<brief_title>Treatment Diabetes Patients With Systolic Heart Failure</brief_title>
	<detailed_description>Investigator Initiated Study : Randomized , double-blinded , active-control clinical trial determine safety efficacy Canagliflozin Sitagliptin patient type 2 diabetes systolic heart failure ( HF ) . The investigator propose study effect Canagliflozin 100 mg v Sitagliptin 100 mg ( administer daily 12 week ) parameter aerobic exercise capacity ventilator efficiency CPET 12 week active treatment . BP , body water content ( Bioelectrical Impedance Analysis [ BIA ] ) , body composition ( Dual-energy X-ray absorptiometry [ DEXA ] ) , cardiac function , diet biomarkers also measure . Subjects evidence leave ventricular hypertrophy undergo cardiac magnetic resonance ( CMR ) imaging .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Major Symptomatic stable heart failure ( New York Heart Association ( NYHA ) functional classification IIIII ) reduce left ventricular ejection fraction ( LVEF ) ≤40 % Peak exercise limit shortness breath associate respiratory exchange ratio ( RER ) &gt; 1.00 ( reflect maximal aerobic effort ) ; Poorly control Type 2 Diabetes Mellitus ( T2DM ) ( HbA1c level 7.0 % 10.0 % treatment regimen include insulin , 6.5 % 10.0 % insulin regimen ) ; Eighteen year age old . Major Type I diabetes ; Open label treatment SodiumGLucose coTransporter ( SGLT ) 2 inhibitor ( within past 3 month ) ; Current treatment thiazolidinedione ( within past 3 month ) ; Chronic Renal Disease define Glomerular Filtration Rate ( GFR ) &lt; 50 ml•min1/1.73m2 accord local laboratory Pregnancy childbearing potential lactating ; Active recent ( within 2 week ) genital/urinary infection ; Concomitant condition treatment would affect completion interpretation study ( i.e , physical inability walk run treadmill Inability give inform consent . Exclusion criterion specific cardiac magnetic resonance ( CMR ) substudy . Estimated GFR &lt; 60 ml•min1/1.73m2 Implantable cardioverter defibrillator , pacemaker implantable metal device compatible CMR scanning ; Severe claustrophobia , inability lay flat 60 minute , contraindication CMR scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Systolic Heart Failure</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sitagliptin Phosphate</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>SGLT2 inhibitor</keyword>
	<keyword>DPPIV inhibitor</keyword>
</DOC>